BiondVax to Present at H.C. Wainwright Bioconnect Virtual Conference
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced its participation in the H.C. Wainwright Bioconnect Virtual Conference from January 10 to 13, 2022. The company will present an overview, and the presentation will be available on-demand for registered attendees. Additionally, a slide deck will be accessible on BiondVax's website. The company focuses on developing innovative products for infectious diseases, including a nanosized antibody pipeline and has completed eight clinical trials, demonstrating a commitment to diverse and commercially viable therapeutic options.
- None.
- None.
JERUSALEM, Jan. 10, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that it will present a company overview at the H.C. Wainwright Bioconnect Virtual Conference.
BiondVax's presentation will be available on-demand from January 10 to 13, 2022 to attendees registering via H.C. Wainwright at https://hcwevents.com/bioconnect/. The slide deck will also be made available on BiondVax's website at https://www.biondvax.com/investors.
About BiondVax
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses. Since its inception, the company has executed eight clinical trials including a seven country, 12,400 participant Phase 3 trial of its vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms, beginning with an innovative nanosized antibody (NanoAb) pipeline. For more information, please visit www.biondvax.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements regarding management's participation in investor conferences. These forward-looking statements reflect management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. Risks and uncertainties include, but are not limited to, the risk that BiondVax will not execute an additional agreement with the Max Planck Society and the University Medical Center Göttingen or that it will be delayed; the risk that the therapeutic and commercial potential of NanoAbs will not be met; the risk of a delay in the preclinical and clinical data for NanoAbs, if any; the risk that BiondVax and EIB will not reach agreement with respect to the restructuring of the loan from European Investment Bank; the risk that BiondVax may not be able to secure additional capital on attractive terms, if at all; the risk that the European Investment Bank may accelerate the loans under its finance contract with BiondVax; risks relating to the COVID-19 (coronavirus) pandemic; BiondVax's ability to acquire rights to additional product opportunities; BiondVax's ability to enter into collaborations on terms acceptable to BiondVax or at all; timing of receipt of regulatory approval of BiondVax's manufacturing facility in Jerusalem, if at all or when required; the risk that the manufacturing facility will not be able to be used for a wide variety of applications and other vaccine and treatment technologies, and the risk that drug development involves a lengthy and expensive process with uncertain outcomes. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's prospectus supplement filed with the Securities and Exchange Commission on December 28, 2021. BiondVax undertakes no obligation to revise or update any forward-looking statement for any reason.
Contact Details
Company: Joshua E. Phillipson | +972 8 930 2529 | j.phillipson@biondvax.com
Investor Relations: Kenny Green | +1 212 378 8040 | kgreen@edisongroup.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/biondvax-to-present-at-hc-wainwright-bioconnect-virtual-conference-301457036.html
SOURCE BiondVax Pharmaceuticals Ltd.
FAQ
When is BiondVax presenting at the H.C. Wainwright Bioconnect Virtual Conference?
Where can I watch BiondVax's presentation from the conference?
What is the focus of BiondVax Pharmaceuticals?
What significant trials has BiondVax completed?
What is the stock symbol for BiondVax Pharmaceuticals?
